Agile Therapeutics Inc (AGRX) WACC Analysis

As of May 29, 2025, Agile Therapeutics Inc (AGRX) carries a Weighted Average Cost of Capital (WACC) of 6.2%. WACC reflects the blended rate Agile Therapeutics Inc must pay to both equity and debt holders.

Within that, the cost of equity is 5.6%, the cost of debt is 7.0%, and the effective tax rate is 26.2%.

Breakdown of WACC Components

• Long-term bond rate: 3.9% – 4.4%
• Equity market risk premium: 4.6% – 5.6%
• Adjusted beta: 0.37 – 0.4
• Additional risk adjustment: 0.0% – 0.5%
• Debt-to-equity ratio: 0.16

What It Means for Investors

With a selected WACC of 6.2%, Agile Therapeutics Inc must ensure any new investment returns exceed this threshold to generate shareholder value. This level reflects an attractive low cost of capital.